Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer

NCT07231445 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: ZG006
DRUG: Serplulimab

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd